Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors

Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors

Summary Epigenetic modulators in combination with proapoptotic drugs have become the standard of care treatment in hematological malignancies. Conversely, these combinations have failed to demonstrate clinical efficacy in solid tumors. To address this discrepancy, we conducted a comprehensive analys...

Full description

Saved in:
Bibliographic Details
Main Authors: Yaiza Senent, Vicente Fresquet, Victoria Jiménez, Karmele Valencia, Francisco Exposito, Patxi San Martín-Úriz, Gracián Camps, Eva Fernández-Pierola, Borja Ruiz-Fernández de Córdoba, Marisol González-Huarriz, Ibon Tamayo, Ana Remírez, Haritz Moreno, Diego Serrano, Daniel Ajona, Marta M. Alonso, Fernando Lecanda, Antonio Pineda-Lucena, Felipe Prósper, Miguel F. Sanmamed, Alfonso Calvo, Jose A. Martinez-Climent, Ruben Pio
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Molecular Cancer
Subjects:
Solid tumors
Epigenetic modulators
CM272
Anti-apoptotic proteins
BCL-XL
A1331852
Online Access:https://doi.org/10.1186/s12943-025-02352-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12943-025-02352-4

Similar Items